Ajinomoto Cambrooke, Inc.
Maureen Jodoin Santos is a seasoned professional with extensive experience in customer service and operations management. Currently serving as a Reimbursement and Client Specialist at Ajinomoto Cambrooke, Inc. since January 2021, Maureen plays a crucial role in advancing medical nutrition solutions. Prior to this, Maureen operated as an Independent Consultant from January 2019 to December 2020 and worked as an ERP Administrator at Dentsply Sirona Implants, North America from February 2015 to January 2019, where responsibilities included planning and implementing ERP systems. Maureen also has a strong background in customer service management, having held positions such as Supervisor of Customer Service and Senior Customer Service Representative at Dentsply Sirona Implants, North America and Customer Service Manager at Allen Medical/Hill-Rom. Throughout a career that began in 1996, Maureen has consistently focused on enhancing customer satisfaction and operational efficiency.
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.